Archive for June 2017
Multiple Myeloma Research Foundation (MMRF) Announces $15 Million Investment In Immunotherapy Initiative
Life Sciences Jobs … Source: BioSpace
Read MoreSarepta Taps Allergan Alum as New CEO
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815×430-sarepta.jpg" NAME"Sarepta Taps Allergan Alum as New CEO" ALT"Sarepta Taps Allergan Alum as New CEO"June 29, 2017By Mark Terry, BioSpace.com Breaking News StaffCambridge, Mass. <A HREF"http://www.biospace.com… Source: BioSpace
Read MoreiTeos Therapeutics Appoints As Vice President, Corporate Development
Life Sciences Jobs … Source: BioSpace
Read MoreRoche to Slash 75 Jobs in Massachusetts, More Consolidation to Come
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815×450-roche.jpg" NAME"Roche to Slash 75 Jobs in Massachusetts, More Consolidation to Come" ALT"Roche to Slash 75 Jobs in Massachusetts, More Consolidation to Come"June 29, 2017By Mark Terry, BioSpace.com Breaking News Staff… Source: BioSpace
Read MoreDova Pharma Announces Pricing Of Initial Public Offering
Life Sciences Jobs … Source: BioSpace
Read MoreSterRx Cited for Sterility Issues
The FDA cited a Plattsburgh, N.Y., outsourcing facility after an inspection in February and March found serious deficiencies in the company’s cleanliness and sterility practices. Source: Drug Industry Daily
Read MoreVA Will Use ICER Drug Assessment Reports in Industry Price Negotiations
The Department of Veterans Affairs is linking up with the Institute for Clinical and Economic Review to support use of ICER’s drug assessment reports in coverage and price negotiations with the pharmaceutical industry. Source: Drug Industry Daily
Read MoreFDA Relaxes 14-Year-Old Recommendations for Medical Gas GMP Compliance
The FDA replaced its 14-year-old draft guidance on cGMPs for the production of medical gases, relaxing some recommendations on expiration dating and warehousing procedures. Source: Drug Industry Daily
Read MoreFDA Taking Comments on BsUFA II Review Assessment Project
For the next generation of the FDA’s biosimilar user fee program, the agency is proposing a new model for reviewing 351(k) applications — allowing for additional communication between review teams and sponsors through development meetings across the submission timeline. Source: Drug Industry Daily
Read MoreFDA Funding Bill Advances in the House
An appropriations bill that would provide $5.2 billion for the FDA in fiscal 2018 got the nod from a House subcommittee Wednesday, bucking the White House’s spending request and giving the agency a slight spending increase for next year. Source: Drug Industry Daily
Read More